Patent · US Active

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

US10814007B2 · kind B2 · utility

2Cited by

4References

15Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Donald C. Foster · Lake Forest Park, US
Brian Bettencourt · Groton, US
Klaus Charisse · Acton, US
Gregory Hinkle · Plymouth, US
Satyanarayana Kuchimanchi · Cambridge, US
Martin Maier · Cambridge, US
Stuart Milstein · Cambridge, US

Key dates

Filing date	Feb 13, 2019
Grant date	Oct 27, 2020
Priority date	—
Expiry date	Feb 13, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/51
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.